June 9, 2020 This may be hard to believe–since we are currently so immersed in the current pandemic—but COVID-19 and the virus that causes it, SARS-CoV-2, are still brand new. As such, there are many things we don’t know about it yet. But one thing that has been pretty clear from the outset is that […] READ MORE
June 15, 2020 The U.S. Food and Drug Administration announced June 15 that it revoked approval called emergency use authorization (EUA) for hydroxychloroquine and chloroquine to be used to treat certain patients who had been hospitalized for COVID-19. The FDA made this decision based on its ongoing analysis of the scientific data from current studies […] READ MORE
June 15, 2020 A recently published study explored how an unconventional treatment method undergoing clinical trials in cancer patients could help lessen the severity of lupus nephritis (inflammation of the kidneys), a common and serious condition in people with lupus. Funded by the Lupus Research Alliance, this study, published in the journal, Science Translational Medicine, […] READ MORE
June 9, 2020 The American College of Rheumatology enlisted 14 experts on infectious diseases and immune system illnesses to develop and publish 25 recommendations on treating lupus and related immune system diseases amid the COVID-19 pandemic. The Lupus Research Alliance would like to share these with the lupus community as information, but recommend talking to […] READ MORE
These are challenging times for everyone-and each of us must stay focused. For the Lupus Research Alliance (LRA) this means safeguarding the health of the lupus community within the new context of the COVID-19 global pandemic. It is imperative that all of us stay calm, safe, and abreast of the most relevant updates on the […] READ MORE
Watch a videotape of our recent webcast: Lupus and Cognitive Health Presented by LRA’s Young Leaders Board People with lupus know only too well the need to avoid stress to prevent flares while optimizing emotional and cognitive wellbeing. But that’s pretty hard to do, especially in this time fraught with societal upheaval amid a global […] READ MORE
Updated June 5, 2020 One of the largest meetings for rheumatologists went virtual this year to enable scientists from around the world to share their latest findings amid the COVID-19 pandemic. EULAR, the e-Congress of the European League Against Rheumatism, runs June 3 -6, and LRA is pleased to share promising results from clinical trials […] READ MORE
June 4, 2020 Racism, bigotry, intolerance and violence are hateful and have no place in American society. The Lupus Research Alliance is committed to ensuring a more caring, loving, equitable and healthy world for those we serve. The lupus community is large and includes a diverse range of racial, religious, ethnic, national and socio-economic groups, […] READ MORE
June 3, 2020 Kezar Life Sciences, Inc. today announced updated results from the Phase 1b (Ph1b) portion of MISSION, a study testing the safety and tolerability of KZR-616 for people with systemic lupus erythematosus (SLE) and those who also have lupus nephritis. The drug showed effectiveness in improving seven measures of disease activity. Both of […] READ MORE
June 3, 2020 The Lupus Research Alliance (LRA) is encouraged by positive data from two studies presented at the European League Against Rheumatism (EULAR) virtual annual congress on the use of the investigational medication anifrolumab as a potential treatment for people with lupus. Anifrolumab is a novel drug that works by blocking a group of […] READ MORE
May 28, 2020 The Lupus Research Alliance is pleased to share that Aurinia Pharmaceuticals Inc submitted a New Drug Application (NDA) to the U.S. FDA for voclosporin as a potential treatment for lupus nephritis with request for a priority review. Lupus nephritis is one of the most common complications of systemic lupus erythematosus, a serious […] READ MORE
NEW YORK, NY, May 28, 2020. More than one third of people with lupus experienced significant issues filling their hydroxychloroquine (Plaquenil) prescriptions during the COVID-19 pandemic, according to results of a new survey conducted by the Lupus Research Alliance (LRA). Hydroxychloroquine shortages in March and April coincided with early data broadly reported in the media […] READ MORE
